Breaking News

A month in, TrumpRx falls short of president's promises

March 5, 2026
President Trump introduces the new TrumpRx website at the White House on Feb. 5.
SAUL LOEB / AFP via Getty Images

A month in, TrumpRx falls short of president's grand promises

Visits appear to be lagging, few drugs have been added, and some deals with pharma companies are still being worked out.

By Daniel Payne


STAT+ | A new mystery emerges about Epstein's involvement in Harvard genetics study

Epstein provided samples in 2013, but the date of his consent was changed to Jan. 31, 2026 one day after the DOJ released the Epstein files.

By Megan Molteni


STAT+ | Science Corp. raises $230 million to bring retinal implant to Americans

The company is awaiting a decision from the Food and Drug Administration on PRIMA, its wireless retinal implant.

By O. Rose Broderick



Scott Olson/Getty Images

STAT+ | Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance

The new model may appeal to companies, but experts fear it could shift the cost of obtaining the weight loss drug onto workers.

By Elaine Chen


STAT+ | Patient health data as a public utility: A former ARPA-H data chief explains

Patients generate vast health data, but private companies monetize it. A policy group proposes treating the data like a regulated utility. Here's how.

By Katie Palmer


STAT+ | More than 50 medical schools will expand nutrition education in agreement with RFK Jr.

Kennedy says doctors need more nutrition education to fight chronic disease. Some experts say changes are long overdue.

By Sarah Todd


Health secretary Robert F. Kennedy Jr. testifies during a Senate Committee on Finance hearing in September 2025.
ALEX WROBLEWSKI/AFP via Getty Images

STAT+ | RFK Jr. has wide discretion to choose evidence to support vaccine decisions, DOJ argues

Pediatricians say Kennedy broke the law in changing vaccine policy. Government counters he has 'authority for evaluating scientific evidence.'

By Anil Oza


STAT+ | The extremism of the FDA's Marks and Prasad has come with costs

In this week's edition of "Adam's Biotech Scorecard," Adam also provides new details on what's at dispute between UniQure and the agency.

By Adam Feuerstein


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments